Oxprenolol

Quality 0.50 · 2 views · Updated 2 months ago

Non-selective beta blocker

title: "Oxprenolol" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["5-ht1a-antagonists", "5-ht1b-antagonists", "abandoned-drugs", "allyl-compounds", "anxiolytics", "beta-blockers", "catechol-ethers", "n-isopropyl-phenoxypropanolamines", "sympathomimetic-amines"] description: "Non-selective beta blocker" topic_path: "arts/music" source: "https://en.wikipedia.org/wiki/Oxprenolol" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Non-selective beta blocker ::

| Verifiedfields = verified | Watchedfields = verified | verifiedrevid = 418877799 | image = Oxprenolol.svg | image_class = skin-invert-image | width = 225px

| tradename = Trasicor, others | Drugs.com = | pregnancy_AU = C | pregnancy_category = | legal_status = Rx-only | routes_of_administration = By mouth | ATC_prefix = C07 | ATC_suffix = AA02

| bioavailability = 20–70% | protein_bound = | metabolism = Liver | metabolites = | elimination_half-life = 1–2 hours | excretion = Kidney Lactic (in lactiferous females)

| IUPHAR_ligand = 7255 | CAS_number_Ref = | CAS_number = 6452-71-7 | PubChem = 4631 | DrugBank_Ref = | DrugBank = DB01580 | ChemSpiderID_Ref = | ChemSpiderID = 4470 | UNII_Ref = | UNII = 519MXN9YZR | KEGG_Ref = | KEGG = D08318 | ChEMBL_Ref = | ChEMBL = 546 | synonyms =

| IUPAC_name = (RS)-1-[2-(allyloxy)phenoxy]-3-(isopropylamino)propan-2-ol | C=15 | H=23 | N=1 | O=3 | chirality = Racemic mixture | SMILES = O(c1ccccc1OC\C=C)CC(O)CNC(C)C | StdInChI_Ref = | StdInChI = 1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3 | StdInChIKey_Ref = | StdInChIKey = CEMAWMOMDPGJMB-UHFFFAOYSA-N

Oxprenolol, sold under the brand name Trasicor among others, is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms, and high blood pressure.

Medical uses

Oxprenolol is used in the treatment of angina pectoris, abnormal heart rhythms, and high blood pressure.

It has been used to treat anxiety as well.

Contraindications

Oxprenolol is a potent beta blocker and should not be administered to asthmatics under any circumstances due to their low beta levels as a result of depletion due to other asthma medication, and because it can cause irreversible, often fatal, airway failure and inflammation.

Pharmacology

Pharmacodynamics

Oxprenolol is a beta blocker. In addition, it has been found to act as an antagonist of the serotonin 5-HT1A and 5-HT1B receptors with respective Ki values of 94.2 nM and 642 nM in rat brain tissue.

Pharmacokinetics

Oxprenolol is a lipophilic beta blocker which passes the blood–brain barrier more easily than hydrophilic beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than beta blockers with more hydrophilic molecules such as atenolol, sotalol, and nadolol. The brain-to-blood ratio of oxprenolol in humans has been found to be 50:1. For comparison, the brain-to-blood ratio of the highly lipophilic propranolol was 15:1 to 26:1 and of the hydrophilic atenolol was 0.2:1.

Chemistry

The experimental log P of oxprenolol is 2.10.

Stereochemistry

Oxprenolol is a chiral compound, the beta blocker is used as a racemate, e. g. a 1:1 mixture of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol. Analytical methods (HPLC) for the separation and quantification of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol in urine and in pharmaceutical formulations have been described in the literature.

: [[File:(±)-Oxoprenolol Structural Formulae V.2.svg|thumb|left|class=skin-invert-image|(R)-(+)-Oxprenolol (top) and (S)-(–)-oxprenolol]]

Society and culture

Brand names

Brand names of oxprenolol include Trasacor, Trasicor, Coretal, Laracor, Slow-Pren, Captol, Corbeton, Slow-Trasicor, Tevacor, Trasitensin, and Trasidex.

References

References

  1. (2021). "The Use of β-Adrenergic Receptor Antagonists in Psychiatry: A Review". J Acad Consult Liaison Psychiatry.
  2. (January 2025). "Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis". J Affect Disord.
  3. (February 1980). "Severe asthma after inadvertent ingestion of oxprenolol". Thorax.
  4. (January 1993). "Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology.
  5. (December 1987). "Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs". European Heart Journal.
  6. (1987). "Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers". Pharmacotherapy.
  7. https://pubchem.ncbi.nlm.nih.gov/compound/4631
  8. https://go.drugbank.com/drugs/DB01580
  9. (2011). "Separation and quantitation of oxprenolol in urine and pharmaceutical formulations by HPLC using a Chiralpak IC and UV detection". Monatshefte für Chemie - Chemical Monthly.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

5-ht1a-antagonists5-ht1b-antagonistsabandoned-drugsallyl-compoundsanxiolyticsbeta-blockerscatechol-ethersn-isopropyl-phenoxypropanolaminessympathomimetic-amines